Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

899 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.
Huang X, Li Y, Zhang J, Yan L, Zhao H, Ding L, Bhatara S, Yang X, Yoshimura S, Yang W, Karol SE, Inaba H, Mullighan C, Litzow M, Zhu X, Zhang Y, Stock W, Jain N, Jabbour E, Kornblau SM, Konopleva M, Pui CH, Paietta E, Evans W, Yu J, Yang JJ. Huang X, et al. Among authors: jabbour e. Cancer Cell. 2024 Apr 8;42(4):552-567.e6. doi: 10.1016/j.ccell.2024.03.003. Cancer Cell. 2024. PMID: 38593781 Free PMC article.
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Giles F, Verstovsek S, Thomas D, Gerson S, Cortes J, Faderl S, Ferrajoli A, Ravandi F, Kornblau S, Garcia-Manero G, Jabbour E, O'Brien S, Karsten V, Cahill A, Yee K, Albitar M, Sznol M, Kantarjian H. Giles F, et al. Among authors: jabbour e. Clin Cancer Res. 2005 Nov 1;11(21):7817-24. doi: 10.1158/1078-0432.CCR-05-1070. Clin Cancer Res. 2005. PMID: 16278404 Clinical Trial.
Adult acute lymphoblastic leukemia.
Jabbour EJ, Faderl S, Kantarjian HM. Jabbour EJ, et al. Mayo Clin Proc. 2005 Nov;80(11):1517-27. doi: 10.4065/80.11.1517. Mayo Clin Proc. 2005. PMID: 16295033 Review.
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, Garcia-Manero G, Ravandi F, Verstovsek S, Borthakur G, Shan J, Cortes J. Fava C, et al. Among authors: jabbour e. Blood. 2009 May 21;113(21):5058-63. doi: 10.1182/blood-2008-10-184960. Epub 2009 Mar 12. Blood. 2009. PMID: 19282457 Free PMC article. Clinical Trial.
Novel therapies for relapsed acute lymphoblastic leukemia.
Fullmer A, O'Brien S, Kantarjian H, Jabbour E. Fullmer A, et al. Among authors: jabbour e. Curr Hematol Malig Rep. 2009 Jul;4(3):148-56. doi: 10.1007/s11899-009-0021-6. Curr Hematol Malig Rep. 2009. PMID: 20425428 Free PMC article. Review.
899 results